Penpulimab

Monoclonal antibody

Also known as AK105

Approvedregulatory verdict

Evidence outlook

Approved: Nasopharyngeal Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USHepatocellular Carcinoma · Phase 3 · investigational in the US

Also approved (2)
CN
  • In combination with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC)akesobio.com
  • In combination with chemotherapy, first-line treatment of locally advanced or metastatic squamous non-small cell lung cancerwww1.hkexnews.hk
Product first approved 2023

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Hepatocellular Carcinoma
NCT05862337 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-05-10 – 2026-12 · Hepatocellular Carcinoma
What this study did
NCT04344158 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-08-11 – 2026-12 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05244642 · Akeso
2022-02-15 – 2026-03-30 · Hodgkin Disease Lymphoma
What this study did
NCT04385550 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-05-20 – 2023-12-31 · Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
What this study did
Phase 2/3 (1)
Hepatocellular Carcinoma
NCT05344924 · Zhongda Hospital
2022-10-12 – 2024-03-31 · Hepatocellular Carcinoma
What this study did
Phase 2 (47)
Hepatocellular Carcinoma
NCT04172571 · Akeso
2018-11-22 – 2022-07-08 · Hepatocellular Carcinoma
What this study did
Nasopharyngeal Carcinoma
NCT05193617 · Sun Yat-sen University
2022-08-17 – 2028-10-01 · Nasopharyngeal Carcinoma
What this study did
NCT05807880 · Sun Yat-sen University
2023-09-01 – 2026-07-01 · Nasopharyngeal Neoplasms
What this study did
NCT05563480 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2022-10-27 – 2025-05-28 · Nasopharyngeal Carcinoma
What this study did
NCT04736810 · Akeso
2021-02-25 – 2023-12-18 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04846634 · Tianjin Medical University Cancer Institute and Hospital
2021-08 – 2028-02 · Resectable Locally Advanced Non-small Cell Lung Cancer
What this study did
NCT06341530 · The First Affiliated Hospital of Zhengzhou University
2024-01-31 – 2025-12-31 · Non-small Cell Lung Cancer
What this study did
NCT05460481 · Hunan Cancer Hospital
2022-06-12 – 2024-12 · Non Small Cell Lung Cancer
What this study did
NCT05485350 · Peking University Third Hospital
2022-09-12 – 2024-10-15 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06586242 · Xijing Hospital
2023-04-03 – 2036-04 · Esophageal Cancer
What this study did
NCT07612098 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-07-01 – 2031-12-31 · Soft Tissue Sarcoma (STS)
What this study did
NCT07904130 · West China Hospital
2026-10-09 – 2029-10-01 · Colo-rectal Cancer
What this study did
NCT05347641 · The First Affiliated Hospital with Nanjing Medical University
2022-06-01 – 2029-06-01 · Primary Central Nervous System Lymphoma
What this study did
NCT06516978 · The First Affiliated Hospital with Nanjing Medical University
2024-10-01 – 2029-04-01 · Diffuse Large B Cell Lymphoma
What this study did
NCT05214222 · Nanfang Hospital, Southern Medical University
2022-09-02 – 2028-09-02 · Advanced Esophageal Squamous Cell Carcinoma
What this study did
NCT05137171 · The First Affiliated Hospital of Zhengzhou University
2022-05-02 – 2027-12-31 · Cervical Cancer
What this study did
NCT06444009 · Lei Liu
2024-07-01 – 2027-12-01 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05949931 · Sun Yat-sen University
2023-10-01 – 2027-12 · Classic Hodgkin Lymphoma
What this study did
NCT06081673 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2023-10-17 – 2027-10-30 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05494060 · The First Affiliated Hospital with Nanjing Medical University
2022-03-16 – 2027-02 · Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer, Digestive System Diseases, Gastric Cancer, Gastrointestinal Neoplasms
What this study did
NCT05260671 · Eye & ENT Hospital of Fudan University
2022-01-25 – 2026-12-25 · Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
What this study did
NCT06500091 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-07 – 2026-12 · Soft Tissue Sarcoma, Melanoma
What this study did
NCT05576480 · Ruijin Hospital
2023-02-06 – 2026-12 · Rectal Cancer, Locally Advanced
What this study did
NCT06051851 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-07-01 – 2026-07-01 · Pancreatic Adenocarcinoma Metastatic
What this study did
NCT05683704 · Tianjin Medical University Cancer Institute and Hospital
2022-09-01 – 2026-05-31 · Recurrent/Refractory Classical Hodgkin's Lymphoma
What this study did
NCT05186558 · The First Affiliated Hospital with Nanjing Medical University
2022-05-15 – 2026-02-15 · Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
What this study did
NCT05028504 · Sichuan Cancer Hospital and Research Institute
2022-05-10 – 2025-12-31 · Gynecological Cancer
What this study did
NCT05229003 · Fudan University
2022-03-09 – 2025-12-31 · Metastatic Colorectal Cancer
What this study did
NCT05001971 · Hunan Cancer Hospital
2021-01-30 – 2025-04-15 · Small Cell Lung Cancer
What this study did
NCT05885399 · Peking Union Medical College Hospital
2023-04-01 – 2025-03-01 · Pheochromocytoma, Metastatic, Pheochromocytoma Malignant, Paraganglioma, Malignant
What this study did
NCT05265962 · The First Affiliated Hospital of Zhengzhou University
2022-12-01 – 2024-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05519202 · The Central Hospital of Lishui City
2022-08-31 – 2024-08-31 · Gastric Cancer
What this study did
NCT05726175 · West China Hospital
2023-03-01 – 2024-08-31 · Breast Cancer
What this study did
NCT04952493 · Peking Union Medical College Hospital
2021-09-15 – 2024-07-20 · Thyroid Cancer
What this study did
NCT05068206 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021-10-08 – 2024-06 · Unresectable Metastatic Colorectal Cancer
What this study did
NCT05493995 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2022-07-21 – 2024-05-01 · Pancreatic Neoplasms
What this study did
NCT05313906 · Henan Cancer Hospital
2022-05-07 – 2024-04-30 · Advanced Gastric Carcinoma, HER2-positive Gastric Cancer
What this study did
NCT05244993 · Liaoning Cancer Hospital & Institute
2022-07 – 2024-03 · Breast Neoplasm Female
What this study did
NCT05033587 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2021-09 – 2023-11-01 · MGMT-Unmethylated Glioblastoma
What this study did
NCT04970914 · Peking Union Medical College Hospital
2021-11-05 – 2023-08-23 · Colorectal Cancer
What this study did
NCT04291248 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-03 – 2022-12 · MSI-H or dMMR Advanced Solid Tumors
What this study did
NCT04207463 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-06-03 – 2021-05-30 · Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
What this study did
NCT04203719 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-05-09 – 2021-05-30 · Advanced Head, Neck and Chest Cancer
What this study did
Phase 1/2 (9)
Hepatocellular Carcinoma
NCT07075419 · West China Hospital
2025-08-01 – 2027-08-01 · Refractory Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT06821503 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025-04-11 – 2028-12 · Advanced Pancreatic Cancer
What this study did
NCT06825494 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2025-04-08 – 2026-09 · Advanced Solid Tumor
What this study did
NCT05834543 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-05-26 – 2025-03-03 · Advanced Esophageal Squamous Cell Carcinoma
What this study did
NCT05783921 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-05-23 – 2025-01 · Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma
What this study did
NCT04803851 · Peking Union Medical College Hospital
2021-05-12 – 2024-06-29 · Anlotinib, Anti-PD-1 Antibody, Advanced Pancreatic Cancer
What this study did
NCT05400876 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2022-06-09 – 2023-10 · Relapsed/Refractory Lymphoma
What this study did
NCT04172506 · Akeso
2019-09-10 – 2022-01-30 · Solid Tumor, Lung Cancer, HCC
What this study did
NCT03722147 · Akeso
2018-08-13 – 2021-12-31 · Hodgkin's Lymphoma
What this study did
Phase 1 (9)
Hepatocellular Carcinoma
NCT07746960 · Nanfang Hospital, Southern Medical University
2025-01-01 – 2027-12-31 · Hepatocellular Carcinoma Non-Resectable
What this study did
NCT06320080 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-05-30 – 2025-11-03 · Advanced Hepatocellular Carcinoma
What this study did
NCT05975645 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-08-15 – 2025-06-04 · Advanced Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT06853769 · The First Affiliated Hospital with Nanjing Medical University
2024-09-01 – 2027-08-01 · Colorectal Cancer
What this study did
NCT05894421 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-06-06 – 2026-01 · Advanced Cancer
What this study did
NCT06297642 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-05-24 – 2024-07-31 · Advanced Malignant Neoplasm
What this study did
NCT05333276 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2022-07-29 – 2024-05 · Advanced Cancers
What this study did
NCT03352531 · Akesobio Australia Pty Ltd
2018-01-02 – 2023-10-28 · Advanced Cancer
What this study did
Phase 4 (2)
Non-Small Cell Lung Cancer
NCT05387109 · Tang-Du Hospital
2022-06-30 – 2024-04-20 · NSCLC
What this study did
Other / comorbidity
NCT05488353 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-09-01 – 2026-04-30 · Bladder Cancer
What this study did
Early phase / not applicable (7)
Other / comorbidity
NCT07764601 · WEI XU
2026-08 – 2029-08 · Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
What this study did
NCT06062563 · Peking Union Medical College Hospital
2023-11-11 – 2025-08-20 · Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
What this study did
NCT05800080 · Xijing Hospital
2023-04 – 2025-02 · Gastric Cancer
What this study did
NCT05784987 · The First Affiliated Hospital with Nanjing Medical University
2023-04-15 – 2025-01-01 · Diffuse Large B-cell Lymphoma
What this study did
NCT05561699 · Shanghai Zhongshan Hospital
2022-09-28 – 2024-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05385900 · Xijing Hospital
2022-06-30 – 2024-06-30 · Gastric Cancer
What this study did
NCT05718778 · Henan Cancer Hospital
2023-03-20 – 2024-03-31 · Soft Tissue Sarcoma
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Non-Small Cell Lung Cancer
NCT07086326 · Yang Fan, MD
2025-07-31 – 2027-12-30 · NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112, Bispecific Antibody
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT06943820 · Akeso
2025-05-21 – 2028-05 · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Hepatocellular Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Penpulimab: this drugPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4)
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1)
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signalNo reviewed efficacy summary in this indication
AmezalpatPhase 3Small moleculePPARα (peroxisome proliferator-activated receptor alpha)not yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 3Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
JS207Phase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NamodenosonPhase 3—Adenosine A3 receptornot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 3Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
PegargiminasePhase 3Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminasenot yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
RYZ801Phase 1/2Radiopharmaceutical—not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
SENTI-301APhase 1Cell therapyGPC3 (CAR-NK, calibrated IL-15)not yet gradedNo reviewed efficacy summary in this indication
SHR-2524Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
AZD7003
—(overall)
Cell therapyGlypican-3 (GPC3)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Penpulimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 3Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04344158 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06081673 · CT.gov ↗
What to watch
2027 (2)
July 2027 (1)
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-07-01 · NCT07075419 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Advanced Pancreatic CancerRecruiting
Est. primary completion 2027-12 · NCT06821503 · CT.gov ↗
What to watch
2028 (4)
August 2028 (1)
Early phase / not applicablePrimary Central Nervous System Lymphoma, Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-08 · NCT07764601 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT06516978 · CT.gov ↗
What to watch
Phase 2Colo-rectal CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07904130 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07381075 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 2Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2031-12-31 · NCT07612098 · CT.gov ↗
What to watch

See the full readout calendar ↗